Plasticity and biological diversity of myeloid derived suppressor cells
Authors:
- 1 April 2018
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 51, 154-161
Abstract
No abstract availableKeywords
Funding Information
- Israel Science Foundation
- National Natural Science Foundation of China
- Israeli Ministry of Health
- Joint German-Israeli Research Program
- Israel Cancer Research Fund
- NOFAR Program of the Academic Research Office of the Chief Scientist
- Ministry of Economy
- Melanoma Research Alliance Funds
- Joseph and Matilda Melnick Funds
This publication has 50 references indexed in Scilit:
- Myeloid-Derived Suppressor Cells Play Crucial Roles in the Regulation of Mouse Collagen-Induced ArthritisThe Journal of Immunology, 2013
- Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic InflammationImmunity, 2013
- Myeloid-Derived Suppressor Cells in Murine Retrovirus-Induced AIDS Inhibit T- and B-Cell ResponsesIn VitroThat Are Used To Define the ImmunodeficiencyJournal of Virology, 2013
- Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast CancerCancer Research, 2013
- Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor functionJournal of Clinical Investigation, 2012
- Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13Blood, 2010
- GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cellsBreast Cancer Research and Treatment, 2009
- Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular CarcinomaCancer Research, 2007
- Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports projectBone Marrow Transplantation, 2007
- Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factorBone Marrow Transplantation, 2000